SurModics' pharma biz sees revenue fall in Q1 2011

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmaceutical drug, Pharmacology

SurModics is still considering “strategic alternatives” for its pharmaceutical business, which has seen revenues continue to decline in the first quarter of 2011.

The pharma division, which covers SurModics’ delivery, injectables, nanoparticle and implant technologies, generated revenue of $2.7m for the three months to December 31, down 6 per cent sequentially.

This decline, coupled with flat sales in its medical device business and a 7 per cent drop in revenue from its in vitro diagnostics division, left SurModics with revenue of $15.2m for the period, down 2 per cent sequentially, on an operating loss of $700,000.

The results follow just weeks after SurModics said it was considering selling the pharmaceutical business and focussing on its devices and diagnostics units, which were also set up in a restructuring move it enacted in October​.

Recently appointed CEO Gary Maharaj, whose predecessor Bruce Barclay led efforts to expand SurModics’ pharma business with the acquisition of Brookwood Pharmaceuticals in 2007, confirmed that the unit’s future was still being examined.

Prior to joining SurModics, my views of this business was [that it was] just a few key decisions away from getting back on the right track. The board and the management team have already made the first decision which is to seek strategic alternatives for the pharmaceuticals business.

I believe that the pharma business has sound long-term growth and profitability prospects in an appropriate strategic setting and financial structure. It is the aim of this process to unlock that value​.”

Maharaj added that: “SurModics is at an important crossroads…by refocusing our efforts within a well-defined core we have an opportunity to build upon our strengths​,” going on to say that management is developing a strategic plan that will be announced in due course.

Related topics: Delivery technologies, Ingredients

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers